

# Comparisons of Non-Small Cell Lung Cancer Treatment Options:

*New Zealand and Australia versus  
European Society for Medical Oncology (ESMO) Guidelines*


Version: 20<sup>th</sup> June 2019



TUAPAPA PŪKAHUKAHU  
LUNG FOUNDATION

New Zealand

# European Society for Medical Oncology (ESMO) Treatment Guidelines algorithm for Non-Small Cell Lung Cancer (NSCLC) as at May 2019



NOTES: 1. lines of therapy not shown for ALK/BRAF/EGFR/ROS1  
 2. nivolumab/ipilimumab for TMB high included in guidelines but excluded here as registration file was withdrawn from EU

Source: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, *Annals of Oncology*, Volume 29, Issue Supplement\_4, 1 October 2018, Pages iv192–iv237

# New Zealand Publicly-Funded Treatment Options compared with ESMO Guidelines for Non-Small Cell Lung Cancer as at 31 May 2019




Source: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, *Annals of Oncology*, Volume 29, Issue Supplement\_4, 1 October 2018, Pages iv192–iv237.

1. Gandhi et al, Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, *NEJM* 2018



# Australian Publicly-Funded Treatment Options compared with ESMO Guidelines for Non-Small Cell Lung Cancer as at 31 May 2019

Chemotherapy  
targeted  
Immunotherapy




NOTES: 1. lines of therapy not shown for ALK/BRAF/EGFR/ROS1  
 2. nivolumab/ipilimumab for TMB high included in guidelines but excluded here as registration file was withdrawn from EU

Source: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, *Annals of Oncology*, Volume 29, Issue Supplement\_4, 1 October 2018, Pages iv192–iv237

# Australian Publicly-Funded Non-Small Cell Lung Cancer Treatment Options as at 31 May 2019

1. Chemotherapy
2. Afatinib
3. Alectinib
4. Atezolizumab
5. Ceritinib
6. Crizotinib
7. Erlotinib
8. Gefitinib
9. Nivolumab
10. Pembrolizumab
11. Osimertinib



Chemotherapy

targeted

Immunotherapy

Source: Australian Pharmaceutical Benefits Scheme

Note: Line of therapy not shown for ALK/EGFR

1. Scarpace SL. Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. *Drugs in Context*. 2015;4:212289. doi:10.7573/dic.212289.
2. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). *American Journal of Cancer Research*. 2015;5(9):2892-2911
3. Paul Hofman: ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice; *Cancers* 2017, 9, 107; doi:10.3390/cancers9080107
4. <https://www.pbs.gov.au/browse/medicine-listing?init> (accessed Jul 18)
5. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=atezolizumab> TECENTRIQ® Roche
6. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=nivolumab> OPDIVO® BMS
7. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=erlotinib> TARCEVA® Roche
8. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=gefitinib> IRESSA® Astra Zeneca
9. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=afatinib> GILOTRIF® Boehringer-Ingelheim – Not available in New Zealand
10. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=crizotinib> XALKORI® Pfizer
11. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=alectinib> ALECENSA® Roche
12. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=ceritinib> ZYKADIA® Novartis – Not available in New Zealand
13. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=Keytruda&r=/> KEYTRUDA® MSD
14. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=osimertinib&r=/> TAGRISSO® Astra Zeneca


15. Gandhi et al, Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, *NEJM* 2018



TUAPAPA PŪKAHUKAHU  
LUNG FOUNDATION  
New Zealand

# New Zealand Publicly-Funded Non-Small Cell Lung Cancer Treatment Options compared with Australia as at 31 May 2019

1. Chemotherapy
2. Erlotinib
3. Gefitinib



Source: Australian Pharmaceutical Benefits Scheme

Note: Line of therapy not shown for ALK/EGFR

1. Scarpace SL. Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. *Drugs in Context*. 2015;4:212289. doi:10.7573/dic.212289.
2. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). *American Journal of Cancer Research*. 2015;5(9):2892-2911
3. Paul Hofman: ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice; *Cancers* 2017, 9, 107; doi:10.3390/cancers9080107
4. <https://www.pharmac.govt.nz/tools-resources/pharmaceutical-schedule/> (accessed Jul 18)
5. <http://www.medsafe.govt.nz/profs/Datasheet/t/tarcevatab.pdf> TARCEVA® Roche
6. <http://www.medsafe.govt.nz/profs/Datasheet/l/lressatab.pdf> IRESSA® Astra Zeneca
7. Gandhi et al, Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, *NEJM* 2018



TUAPAPA PŪKAHUKAHU  
LUNG FOUNDATION  
New Zealand

# New Zealand Publicly-Funded Non-Small Cell Lung Cancer Treatment Options compared with Australia as at 31 May 2019

